Since many patients with CRC have aberrant TGF-β/SMAD4 signaling which may affect transcriptional regulation, localization and stability of those transcripts, their biomarker potential should be further investigated in the human tissue samples of CRC patients by combined analysis of SMAD4-209 and SMAD4-213 expression levels. The gene discussed is SMAD4; the disease is colorectal carcinoma.